Free Trial

NKGen Biotech (NKGN) News Today

NKGen Biotech logo
$0.13 -0.01 (-8.62%)
As of 08/28/2025 12:37 PM Eastern

NKGN Latest News

NKGen Biotech Enters Stock Purchase Agreement
NKGen Biotech Chairman & CEO Paul Y. Song, M.D.
NKGen Biotech presents data from Phase 1/2a trial of troculeucel
NKGen Biotech announces administration of first dose of troculeucel
NKGen administers first troculeucel dose under compassionate use program
NKGen Biotech appoints Anita Fletcher as PI for Phase 2a troculeucel trial
NKGen Biotech announces publication of Phase 1 troculeucel trial results
NKGen Biotech, Inc. (NKGN)
NKGen Biotech Awards Stock Options to Executives
NKGen Biotech Secures Key Role in NKMax Deal
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
NKGen Biotech gets Nasdaq notice related to delayed quarterly report
NKGen Flat on Presentation of Alzheimer's Treatment
Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NKGN Media Mentions By Week

NKGN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NKGN
News Sentiment

0.00

1.03

Average
Medical
News Sentiment

NKGN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NKGN Articles
This Week

0

1

NKGN Articles
Average Week

Get the Latest News and Ratings for NKGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for NKGen Biotech and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NYSE:NKGN) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners